Evidence map›Paper›PMID 38049659›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2024

Florbetapir PET-assessed demyelination is associated with faster tau accumulation in an APOE ε4-dependent manner.

Anna Rubinski, Anna Dewenter, Lukai Zheng, Nicolai Franzmeier, Henry Stephenson, Yuetiva Deming, Marco Duering, Benno Gesierich, Jannis Denecke, An-Vi Pham and 3 more

Open access · hybridAbstract read
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Emerging Role of Oligodendrocytes Malfunction in the Progression of Alzheimer's Disease.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025
    Review
  4. Reduced myelin contributes to cognitive impairment in patients with monogenic small vessel disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Anna RubinskiInstitute for Stroke and Dementia Research, University Hospital, Ludwig-Maximilian-University Munich, Munich, Germany.
Anna DewenterInstitute for Stroke and Dementia Research, University Hospital, Ludwig-Maximilian-University Munich, Munich, Germany.
Lukai ZhengInstitute for Stroke and Dementia Research, University Hospital, Ludwig-Maximilian-University Munich, Munich, Germany.
Nicolai FranzmeierInstitute for Stroke and Dementia Research, University Hospital, Ludwig-Maximilian-University Munich, Munich, Germany.
Henry StephensonDepartment of Medicine, School of Medicine and Public Health, University of Wisconsin- Madison, Madison, WI, USA.
Yuetiva DemingDepartment of Medicine, School of Medicine and Public Health, University of Wisconsin- Madison, Madison, WI, USA.
Marco DueringInstitute for Stroke and Dementia Research, University Hospital, Ludwig-Maximilian-University Munich, Munich, Germany.
Benno GesierichMedical Image Analysis Center (MIAC) and Department of Biomedical Engineering, University of Basel, Basel, Switzerland.
Jannis DeneckeInstitute for Stroke and Dementia Research, University Hospital, Ludwig-Maximilian-University Munich, Munich, Germany.
An-Vi PhamInstitute for Stroke and Dementia Research, University Hospital, Ludwig-Maximilian-University Munich, Munich, Germany.
Barbara BendlinDepartment of Medicine, School of Medicine and Public Health, University of Wisconsin- Madison, Madison, WI, USA.
Michael EwersInstitute for Stroke and Dementia Research, University Hospital, Ludwig-Maximilian-University Munich, Munich, Germany. Michael.ewers@med.uni-muenchen.de.
Alzheimer’s Disease Neuroimaging Initiative
Ludwig-Maximilians-Universität München · DEUniversity of Wisconsin–Madison · USGerman Center for Neurodegenerative Diseases · DETechnical University of Munich · DEUniversity of Basel · CH

Funding

White matter degeneration: biomarkers in preclinical Alzheimer's DiseaseR01AG037639 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI BENDLIN, BARBARA BRIGITTA · 2012 to 2023
$5.3M
Algebraic Formulations for Characterizing Structural Brain Connectivity Changes and Pathology Transmission Networks in Preclinical Alzheimer's DiseaseRF1AG059312 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI BENDLIN, BARBARA BRIGITTA, SINGH, VIKAS · 2019 to 2019
$1.8M
Maximizing Power in AD Clinical Trials via Multimodal Machine LearningR01AG040396 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI SINGH, VIKAS · 2012 to 2015
$1.1M
NIA NIH HHS R01 AG037639NIA NIH HHS R01 AG040396NIA NIH HHS RF1 AG059312
6 · The paper itself

Abstract

purposeThe main objectives were to test whether (1) a decrease in myelin is associated with enhanced rate of fibrillar tau accumulation and cognitive decline in Alzheimer's disease, and (2) whether apolipoprotein E (APOE) ε4 genotype is associated with worse myelin decrease and thus tau accumulation.

methodsTo address our objectives, we repurposed florbetapir-PET as a marker of myelin in the white matter (WM) based on previous validation studies showing that beta-amyloid (Aβ) PET tracers bind to WM myelin. We assessed 43 Aβ-biomarker negative (Aβ-) cognitively normal participants and 108 Aβ+ participants within the AD spectrum with florbetapir-PET at baseline and longitudinal flortaucipir-PET as a measure of fibrillar tau (tau-PET) over ~ 2 years. In linear regression analyses, we tested florbetapir-PET in the whole WM and major fiber tracts as predictors of tau-PET accumulation in a priori defined regions of interest (ROIs) and fiber-tract projection areas. In mediation analyses we tested whether tau-PET accumulation mediates the effect of florbetapir-PET in the whole WM on cognition. Finally, we assessed the role of myelin alteration on the association between APOE and tau-PET accumulation.

resultsLower florbetapir-PET in the whole WM or at a given fiber tract was predictive of faster tau-PET accumulation in Braak stages or the connected grey matter areas in Aβ+ participants. Faster tau-PET accumulation in higher cortical brain areas mediated the association between a decrease in florbetapir-PET in the WM and a faster rate of decline in global cognition and episodic memory. APOE ε4 genotype was associated with a worse decrease in the whole WM florbetapir-PET and thus enhanced tau-PET accumulation.

conclusionMyelin alterations are associated in an APOE ε4 dependent manner with faster tau progression and cognitive decline, and may therefore play a role in the etiology of AD.

Indexed as

Alzheimer DiseaseAniline CompoundsCognitive DysfunctionDemyelinating DiseasesEthylene GlycolsAmyloid beta-PeptidesApolipoprotein E4Apolipoproteins EBrainHumansPositron-Emission Tomographytau ProteinsAmyloid beta-PeptidesAniline CompoundsApolipoprotein E4Apolipoproteins EEthylene Glycolsflorbetapirtau ProteinsAPOEFlorbetapir-PETMyelinTau

Identifiers

PMID38049659
PMCPMC10881623
OpenAlexW4389326902

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.